| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Gastrointestinal Stromal Tumors | 13 | 2019 | 84 | 3.68 | Why? |
| Interactive Ventilatory Support | 2 | 2017 | 25 | 1.38 | Why? |
| Cell Movement | 5 | 2018 | 695 | 1.35 | Why? |
| Imatinib Mesylate | 6 | 2018 | 327 | 1.28 | Why? |
| Noninvasive Ventilation | 6 | 2021 | 2329 | 1.26 | Why? |
| Receptor, Angiotensin, Type 2 | 2 | 2018 | 190 | 1.23 | Why? |
| Stomach Neoplasms | 7 | 2019 | 477 | 1.18 | Why? |
| Hypotension | 2 | 2021 | 392 | 1.09 | Why? |
| Tidal Volume | 4 | 2019 | 565 | 0.96 | Why? |
| Ischemic Preconditioning | 2 | 2018 | 43 | 0.90 | Why? |
| Antineoplastic Agents | 6 | 2018 | 3550 | 0.80 | Why? |
| Receptors, CXCR | 2 | 2018 | 8 | 0.79 | Why? |
| Vasopressins | 1 | 2020 | 70 | 0.78 | Why? |
| Norepinephrine | 1 | 2020 | 152 | 0.76 | Why? |
| Gastrointestinal Neoplasms | 6 | 2018 | 392 | 0.73 | Why? |
| cdc42 GTP-Binding Protein | 1 | 2017 | 12 | 0.72 | Why? |
| Cytochrome P-450 CYP2C19 | 1 | 2017 | 25 | 0.72 | Why? |
| Chemokine CXCL12 | 1 | 2018 | 74 | 0.72 | Why? |
| Focal Adhesion Kinase 1 | 1 | 2017 | 15 | 0.71 | Why? |
| Microsatellite Instability | 1 | 2018 | 57 | 0.71 | Why? |
| Head Protective Devices | 1 | 2019 | 163 | 0.70 | Why? |
| rhoA GTP-Binding Protein | 1 | 2017 | 24 | 0.70 | Why? |
| Respiratory Dead Space | 1 | 2017 | 36 | 0.69 | Why? |
| Anesthetics, Inhalation | 1 | 2018 | 82 | 0.67 | Why? |
| Myocardial Reperfusion Injury | 1 | 2018 | 129 | 0.65 | Why? |
| Acute Lung Injury | 2 | 2018 | 904 | 0.64 | Why? |
| Respiratory Physiological Phenomena | 1 | 2017 | 157 | 0.62 | Why? |
| Palliative Care | 3 | 2020 | 2665 | 0.58 | Why? |
| Fungi | 1 | 2018 | 471 | 0.57 | Why? |
| Propofol | 1 | 2017 | 172 | 0.56 | Why? |
| DNA Methylation | 1 | 2019 | 688 | 0.55 | Why? |
| Chemotherapy, Adjuvant | 1 | 2017 | 606 | 0.55 | Why? |
| Cell Proliferation | 3 | 2018 | 1973 | 0.54 | Why? |
| Shock, Septic | 2 | 2020 | 1313 | 0.49 | Why? |
| Candidiasis, Invasive | 3 | 2017 | 107 | 0.46 | Why? |
| Angiotensin II | 1 | 2017 | 601 | 0.44 | Why? |
| Conscious Sedation | 1 | 2013 | 222 | 0.44 | Why? |
| Nomograms | 4 | 2021 | 790 | 0.43 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2018 | 861 | 0.42 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 3832 | 0.42 | Why? |
| Gastrectomy | 4 | 2019 | 225 | 0.39 | Why? |
| Intensive Care Units | 11 | 2020 | 29594 | 0.38 | Why? |
| Adrenal Cortex Hormones | 3 | 2020 | 6537 | 0.37 | Why? |
| Respiration, Artificial | 10 | 2020 | 22116 | 0.37 | Why? |
| Protein Kinase Inhibitors | 2 | 2018 | 1585 | 0.37 | Why? |
| Polymorphism, Genetic | 2 | 2017 | 1074 | 0.36 | Why? |
| Critical Illness | 9 | 2021 | 17281 | 0.36 | Why? |
| Respiratory Insufficiency | 4 | 2020 | 7301 | 0.36 | Why? |
| Acute Kidney Injury | 5 | 2020 | 5762 | 0.36 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.34 | Why? |
| Peritoneal Neoplasms | 2 | 2018 | 110 | 0.33 | Why? |
| Organ Dysfunction Scores | 5 | 2020 | 1475 | 0.33 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2018 | 1322 | 0.32 | Why? |
| Sepsis | 5 | 2019 | 3517 | 0.32 | Why? |
| Critical Care | 7 | 2021 | 14081 | 0.32 | Why? |
| Adrenal Glands | 1 | 2007 | 98 | 0.32 | Why? |
| Blood Pressure | 2 | 2017 | 2198 | 0.30 | Why? |
| Masks | 2 | 2019 | 8528 | 0.29 | Why? |
| Cross-Over Studies | 2 | 2019 | 867 | 0.28 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.28 | Why? |
| Adrenal Insufficiency | 1 | 2007 | 190 | 0.28 | Why? |
| Dexmedetomidine | 2 | 2018 | 130 | 0.28 | Why? |
| Disease-Free Survival | 6 | 2019 | 1654 | 0.28 | Why? |
| Aged | 37 | 2021 | 215776 | 0.27 | Why? |
| Signal Transduction | 3 | 2017 | 7207 | 0.27 | Why? |
| China | 22 | 2021 | 50654 | 0.27 | Why? |
| Middle Aged | 43 | 2021 | 270681 | 0.27 | Why? |
| Blood Gas Analysis | 2 | 2017 | 893 | 0.26 | Why? |
| APACHE | 3 | 2020 | 682 | 0.25 | Why? |
| Humans | 79 | 2021 | 930598 | 0.25 | Why? |
| Male | 46 | 2021 | 367725 | 0.25 | Why? |
| Antifungal Agents | 3 | 2018 | 1828 | 0.24 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.23 | Why? |
| Female | 45 | 2021 | 380317 | 0.22 | Why? |
| Neoplasm Recurrence, Local | 2 | 2019 | 1063 | 0.22 | Why? |
| Aged, 80 and over | 19 | 2020 | 88759 | 0.22 | Why? |
| Ki-67 Antigen | 2 | 2018 | 139 | 0.21 | Why? |
| Positive-Pressure Respiration | 2 | 2018 | 1160 | 0.19 | Why? |
| Drug Monitoring | 2 | 2018 | 1408 | 0.19 | Why? |
| Crk-Associated Substrate Protein | 1 | 2018 | 3 | 0.19 | Why? |
| E2F4 Transcription Factor | 1 | 2018 | 15 | 0.19 | Why? |
| Prospective Studies | 10 | 2021 | 43301 | 0.19 | Why? |
| Pulmonary Gas Exchange | 2 | 2019 | 414 | 0.19 | Why? |
| Air Pressure | 1 | 2019 | 119 | 0.19 | Why? |
| Malate Dehydrogenase | 1 | 2018 | 3 | 0.19 | Why? |
| Retrospective Studies | 21 | 2021 | 105322 | 0.19 | Why? |
| Jaundice, Obstructive | 1 | 2018 | 24 | 0.19 | Why? |
| Mice, Inbred C57BL | 3 | 2018 | 5542 | 0.19 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.19 | Why? |
| Adrenergic alpha-2 Receptor Agonists | 1 | 2018 | 47 | 0.19 | Why? |
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 14 | 0.18 | Why? |
| NADP | 1 | 2018 | 41 | 0.18 | Why? |
| Lung | 4 | 2020 | 31049 | 0.18 | Why? |
| DNA Mismatch Repair | 1 | 2018 | 25 | 0.18 | Why? |
| Mitosis | 1 | 2018 | 43 | 0.18 | Why? |
| Patient Comfort | 1 | 2019 | 74 | 0.18 | Why? |
| Randomized Controlled Trials as Topic | 6 | 2020 | 10649 | 0.18 | Why? |
| Capecitabine | 1 | 2018 | 51 | 0.18 | Why? |
| Receptor, Insulin | 1 | 2017 | 18 | 0.18 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 343 | 0.18 | Why? |
| Genetic Markers | 1 | 2019 | 318 | 0.18 | Why? |
| Necrosis | 2 | 2018 | 532 | 0.18 | Why? |
| Hyaluronan Receptors | 1 | 2018 | 61 | 0.18 | Why? |
| Microarray Analysis | 1 | 2019 | 262 | 0.18 | Why? |
| Chromatography, Liquid | 2 | 2021 | 640 | 0.18 | Why? |
| Adult | 31 | 2021 | 244371 | 0.18 | Why? |
| Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 121 | 0.18 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2018 | 85 | 0.17 | Why? |
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 59 | 0.17 | Why? |
| Pain Threshold | 1 | 2017 | 46 | 0.17 | Why? |
| Microscopy, Fluorescence | 1 | 2018 | 335 | 0.17 | Why? |
| Morphine | 1 | 2017 | 71 | 0.17 | Why? |
| Molecular Sequence Annotation | 1 | 2019 | 478 | 0.17 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.17 | Why? |
| Myelopoiesis | 1 | 2018 | 116 | 0.17 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.17 | Why? |
| Pulmonary Surfactants | 1 | 2019 | 128 | 0.16 | Why? |
| Lipocalin-2 | 1 | 2018 | 156 | 0.16 | Why? |
| Protein-Tyrosine Kinases | 1 | 2018 | 158 | 0.16 | Why? |
| Pain, Postoperative | 2 | 2017 | 289 | 0.16 | Why? |
| Neoplasm Staging | 3 | 2019 | 1999 | 0.16 | Why? |
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 48 | 0.16 | Why? |
| Creatine Kinase, MB Form | 1 | 2018 | 259 | 0.16 | Why? |
| Isoxazoles | 1 | 2016 | 68 | 0.16 | Why? |
| Prognosis | 12 | 2020 | 32490 | 0.15 | Why? |
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 291 | 0.15 | Why? |
| Tomography | 1 | 2017 | 183 | 0.15 | Why? |
| Leukopenia | 1 | 2018 | 280 | 0.15 | Why? |
| Lung Compliance | 1 | 2017 | 243 | 0.15 | Why? |
| Hypoxia | 3 | 2020 | 3626 | 0.15 | Why? |
| Length of Stay | 5 | 2020 | 11042 | 0.15 | Why? |
| Chemoembolization, Therapeutic | 1 | 2016 | 144 | 0.14 | Why? |
| Electric Impedance | 1 | 2017 | 283 | 0.14 | Why? |
| Liver Neoplasms | 2 | 2018 | 1666 | 0.14 | Why? |
| Health Status Indicators | 1 | 2018 | 341 | 0.14 | Why? |
| Respiratory Rate | 1 | 2019 | 691 | 0.14 | Why? |
| Mitotic Index | 3 | 2018 | 19 | 0.14 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.14 | Why? |
| Renal Replacement Therapy | 3 | 2020 | 1530 | 0.14 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.13 | Why? |
| Anniversaries and Special Events | 1 | 2015 | 127 | 0.13 | Why? |
| Lipopolysaccharides | 1 | 2018 | 848 | 0.13 | Why? |
| RNA, Long Noncoding | 1 | 2018 | 408 | 0.13 | Why? |
| Oxygen Consumption | 1 | 2018 | 711 | 0.13 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.13 | Why? |
| Drug Resistance, Neoplasm | 1 | 2017 | 447 | 0.13 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.13 | Why? |
| Databases, Genetic | 1 | 2019 | 1127 | 0.13 | Why? |
| Receptors, Immunologic | 1 | 2017 | 555 | 0.13 | Why? |
| Cannula | 1 | 2018 | 750 | 0.13 | Why? |
| Developed Countries | 1 | 2017 | 500 | 0.13 | Why? |
| Candida | 1 | 2017 | 425 | 0.12 | Why? |
| Hypnotics and Sedatives | 1 | 2018 | 624 | 0.12 | Why? |
| Intubation, Intratracheal | 2 | 2020 | 3962 | 0.12 | Why? |
| Mice | 5 | 2018 | 21357 | 0.12 | Why? |
| Troponin T | 1 | 2018 | 771 | 0.12 | Why? |
| Kaplan-Meier Estimate | 4 | 2017 | 4260 | 0.12 | Why? |
| Anti-Bacterial Agents | 3 | 2019 | 10083 | 0.12 | Why? |
| Leg | 1 | 2013 | 142 | 0.12 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.12 | Why? |
| Combined Modality Therapy | 2 | 2020 | 3395 | 0.12 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.12 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.12 | Why? |
| Biomarkers, Tumor | 2 | 2018 | 1314 | 0.12 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.11 | Why? |
| Nursing Staff | 1 | 2019 | 542 | 0.11 | Why? |
| Follow-Up Studies | 6 | 2019 | 17020 | 0.11 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1014 | 0.11 | Why? |
| Adjuvants, Immunologic | 1 | 2020 | 1709 | 0.11 | Why? |
| Adenocarcinoma | 1 | 2017 | 651 | 0.10 | Why? |
| Anemia | 1 | 2018 | 789 | 0.10 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.10 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.10 | Why? |
| Animals | 10 | 2018 | 78931 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Pandemics | 12 | 2020 | 389249 | 0.10 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2011 | 9659 | 0.10 | Why? |
| Incidence | 4 | 2020 | 25622 | 0.10 | Why? |
| Troponin I | 1 | 2018 | 1298 | 0.10 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.10 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.10 | Why? |
| Single-Blind Method | 1 | 2013 | 1283 | 0.10 | Why? |
| Treatment Outcome | 8 | 2018 | 51732 | 0.09 | Why? |
| Tandem Mass Spectrometry | 3 | 2021 | 1031 | 0.09 | Why? |
| Smoking Cessation | 1 | 2017 | 826 | 0.09 | Why? |
| Patient Compliance | 1 | 2019 | 1468 | 0.09 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.09 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.09 | Why? |
| Survival Analysis | 5 | 2020 | 7592 | 0.09 | Why? |
| Gene Expression Profiling | 1 | 2019 | 3788 | 0.09 | Why? |
| Adrenocorticotropic Hormone | 1 | 2007 | 107 | 0.09 | Why? |
| Income | 1 | 2017 | 1564 | 0.09 | Why? |
| Analgesics, Opioid | 1 | 2017 | 1070 | 0.09 | Why? |
| Acute Disease | 2 | 2017 | 6029 | 0.09 | Why? |
| Influenza in Birds | 1 | 2013 | 528 | 0.08 | Why? |
| Risk Assessment | 4 | 2019 | 25439 | 0.08 | Why? |
| Bone Marrow Cells | 2 | 2018 | 186 | 0.08 | Why? |
| Mice, Nude | 2 | 2018 | 340 | 0.08 | Why? |
| Lentivirus | 2 | 2018 | 310 | 0.08 | Why? |
| Xenograft Model Antitumor Assays | 2 | 2017 | 274 | 0.08 | Why? |
| ROC Curve | 4 | 2021 | 6024 | 0.08 | Why? |
| Survival Rate | 5 | 2019 | 9206 | 0.08 | Why? |
| Multivariate Analysis | 4 | 2018 | 5440 | 0.08 | Why? |
| Hospital Mortality | 4 | 2018 | 22087 | 0.08 | Why? |
| Proportional Hazards Models | 4 | 2020 | 6543 | 0.08 | Why? |
| Gene Frequency | 1 | 2011 | 1210 | 0.08 | Why? |
| Blood Volume | 1 | 2006 | 90 | 0.08 | Why? |
| Carcinoma, Hepatocellular | 1 | 2016 | 1222 | 0.08 | Why? |
| Shock, Hemorrhagic | 1 | 2006 | 81 | 0.08 | Why? |
| Cross Infection | 2 | 2018 | 8675 | 0.08 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.07 | Why? |
| Drugs, Chinese Herbal | 1 | 2021 | 2760 | 0.07 | Why? |
| Alleles | 1 | 2011 | 1557 | 0.07 | Why? |
| Disease Progression | 3 | 2019 | 13580 | 0.07 | Why? |
| RNA, Messenger | 1 | 2019 | 5131 | 0.07 | Why? |
| Oxygen Inhalation Therapy | 1 | 2018 | 3629 | 0.07 | Why? |
| Lung Diseases | 1 | 2018 | 2361 | 0.07 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 5002 | 0.07 | Why? |
| HEK293 Cells | 1 | 2018 | 8394 | 0.07 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.07 | Why? |
| Young Adult | 10 | 2021 | 93724 | 0.07 | Why? |
| Glucose | 2 | 2018 | 573 | 0.06 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.06 | Why? |
| Age Factors | 3 | 2018 | 21039 | 0.06 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.06 | Why? |
| Cell Survival | 2 | 2018 | 1581 | 0.06 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.06 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.06 | Why? |
| Genetic Vectors | 2 | 2018 | 1600 | 0.05 | Why? |
| Influenza A virus | 1 | 2013 | 2234 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.05 | Why? |
| Biomarkers | 3 | 2019 | 23361 | 0.05 | Why? |
| Receptors, Virus | 1 | 2017 | 5659 | 0.05 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2017 | 5837 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.05 | Why? |
| Predictive Value of Tests | 3 | 2021 | 9537 | 0.05 | Why? |
| Diffusion Chambers, Culture | 1 | 2018 | 2 | 0.05 | Why? |
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 13 | 0.05 | Why? |
| Plasma | 2 | 2020 | 1809 | 0.05 | Why? |
| Adenovirus E1A Proteins | 1 | 2018 | 1 | 0.05 | Why? |
| Genotype | 1 | 2011 | 4697 | 0.05 | Why? |
| Proto-Oncogene Proteins c-ets | 1 | 2018 | 5 | 0.05 | Why? |
| Adipogenesis | 1 | 2018 | 38 | 0.05 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.05 | Why? |
| Smad4 Protein | 1 | 2018 | 15 | 0.05 | Why? |
| Fever | 1 | 2016 | 7795 | 0.05 | Why? |
| Cell Line, Tumor | 2 | 2018 | 3608 | 0.05 | Why? |
| Societies, Medical | 1 | 2015 | 6907 | 0.05 | Why? |
| Receptors, CXCR4 | 1 | 2018 | 83 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.05 | Why? |
| Analgesia, Patient-Controlled | 1 | 2017 | 20 | 0.04 | Why? |
| Cell Hypoxia | 1 | 2018 | 141 | 0.04 | Why? |
| Cell Cycle Checkpoints | 1 | 2018 | 126 | 0.04 | Why? |
| Medical Records | 1 | 2021 | 513 | 0.04 | Why? |
| Critical Care Outcomes | 1 | 2018 | 138 | 0.04 | Why? |
| Osteogenesis | 1 | 2018 | 95 | 0.04 | Why? |
| Heterografts | 1 | 2018 | 203 | 0.04 | Why? |
| Mice, Inbred NOD | 1 | 2017 | 134 | 0.04 | Why? |
| Gene Expression Regulation, Developmental | 1 | 2018 | 159 | 0.04 | Why? |
| Disulfides | 1 | 2018 | 161 | 0.04 | Why? |
| Discriminant Analysis | 1 | 2017 | 170 | 0.04 | Why? |
| Mice, SCID | 1 | 2017 | 225 | 0.04 | Why? |
| Tumor Cells, Cultured | 1 | 2017 | 254 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Coculture Techniques | 1 | 2017 | 258 | 0.04 | Why? |
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 49 | 0.04 | Why? |
| Preoperative Period | 1 | 2018 | 271 | 0.04 | Why? |
| Adolescent | 5 | 2018 | 86841 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Postoperative Nausea and Vomiting | 1 | 2016 | 30 | 0.04 | Why? |
| Vasoconstrictor Agents | 1 | 2020 | 714 | 0.04 | Why? |
| Genetic Predisposition to Disease | 1 | 2011 | 4027 | 0.04 | Why? |
| Stroke Volume | 1 | 2006 | 2153 | 0.04 | Why? |
| Tissue Distribution | 1 | 2018 | 483 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.04 | Why? |
| Tumor Burden | 1 | 2017 | 369 | 0.04 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2017 | 350 | 0.04 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.04 | Why? |
| Proto-Oncogene Proteins | 1 | 2018 | 340 | 0.04 | Why? |
| CTLA-4 Antigen | 1 | 2017 | 282 | 0.04 | Why? |
| Bilirubin | 1 | 2018 | 503 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Geography, Medical | 1 | 2017 | 537 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Time Factors | 4 | 2019 | 31397 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.03 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Cigarette Smoking | 1 | 2017 | 337 | 0.03 | Why? |
| Respiratory Therapy | 1 | 2020 | 918 | 0.03 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Pain Measurement | 1 | 2016 | 533 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Italy | 1 | 2017 | 38444 | 0.03 | Why? |
| Candidiasis | 1 | 2017 | 334 | 0.03 | Why? |
| Quality Indicators, Health Care | 1 | 2017 | 580 | 0.03 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Postoperative Care | 1 | 2017 | 755 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.03 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.03 | Why? |
| Down-Regulation | 1 | 2018 | 1416 | 0.03 | Why? |
| Program Evaluation | 1 | 2020 | 1929 | 0.03 | Why? |
| Poultry | 1 | 2013 | 437 | 0.03 | Why? |
| Reassortant Viruses | 1 | 2013 | 287 | 0.03 | Why? |
| Antimicrobial Stewardship | 1 | 2019 | 931 | 0.03 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.03 | Why? |
| Hospitals | 2 | 2020 | 11793 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.03 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.03 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.02 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Liver Function Tests | 1 | 2016 | 1325 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.02 | Why? |
| Limit of Detection | 1 | 2017 | 2698 | 0.02 | Why? |
| Kidney Diseases | 1 | 2020 | 1434 | 0.02 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.02 | Why? |
| History, 20th Century | 1 | 2015 | 1282 | 0.02 | Why? |
| Influenza, Human | 1 | 2013 | 10779 | 0.02 | Why? |
| Medicine, Chinese Traditional | 1 | 2020 | 2255 | 0.02 | Why? |
| History, 21st Century | 1 | 2015 | 1849 | 0.02 | Why? |
| Blood Volume Determination | 1 | 2006 | 4 | 0.02 | Why? |
| Preoperative Care | 1 | 2017 | 1515 | 0.02 | Why? |
| Propensity Score | 1 | 2016 | 2690 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Apoptosis | 1 | 2017 | 2335 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2020 | 2093 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.02 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
| Oxygen | 1 | 2019 | 3715 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2013 | 2830 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Fatal Outcome | 1 | 2013 | 3438 | 0.02 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.01 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.01 | Why? |
| Liver | 1 | 2016 | 4007 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.01 | Why? |
| Dogs | 1 | 2006 | 2529 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.01 | Why? |
| Phylogeny | 1 | 2013 | 13341 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 11367 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 13720 | 0.01 | Why? |
| Genome, Viral | 1 | 2013 | 13157 | 0.01 | Why? |
| Hospitalization | 1 | 2017 | 54280 | 0.00 | Why? |